News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CASI Pharmaceuticals  (ENMD) To Start China Trial Of Cancer Drug



7/21/2014 4:32:15 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CASI Pharmaceuticals, a US company formerly known as EntreMed, received CFDA permission to start a China Phase II trial of its proprietary drug for triple-negative breast cancer. The trial will be combined with a US Phase II trial, already in progress. CASI says that ENMD-2076, an orally-active, Aurora A/angiogenic kinase inhibitor, has a unique kinase selectivity profile and multiple mechanisms of action.

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES